newsBaxter BioScience acquires Oncaspar portfolio for leukaemia for $900m13 May 2015 | By Victoria White (European Pharmaceutical Review)Baxter has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau for US $900 million.